|
Combretastatin A4 Phosphate |
|---|---|
| Trade Name | |
| Orphan Indication | Medullary thyroid cancer |
| USA Market Approval | USA |
| USA Designation Date | 2003-07-23 00:00:00 |
| Sponsor | Mateon Therapeutics, Inc.;701 Gateway Boulevard, Suite 210;South San Francisco, California, 94080 |
